residues Glu 39 and Asp 168. The three most active compounds against both commercial and rat liver DNase I (31, 38, and 41) exhibited favorable physico-chemical, pharmacokinetic, and toxicological properties. These observations could be utilized to guide the rational design and optimization of novel thiazolidinone inhibitors. Thiazolidinones as novel DNase I inhibitors could have potential therapeutic
合成了十二种新的
噻唑烷酮,并与41种先前合成的
噻唑烷酮一起在体外评估了对
脱氧核糖核酸酶I(DNase I)的抑制活性。十种化合物抑制商业牛胰腺DNase I的IC50低于200μM,并显示出比作为阳性对照的
结晶紫(IC50 = 365.90±47.33μM)更有效的DNase I
抑制剂。此外,三种化合物对大鼠肝脏匀浆中的DNase I具有活性,IC50低于200μM。(3-甲基-1,4-二氧
噻唑啉-2-亚甲基)-N-(2-苯基乙基)乙酰胺(41)对商业和大鼠肝脏DNase I的DNase I抑制作用最强,IC50值为115.96±11.70,分别为151.36±15.85μM。Site Finder和分子对接定义了
噻唑烷酮与DNase I最重要的催化残基的相互作用,包括与残基His 134和His 252的H-受体相互作用和/或与残基Glu 39和Asp 168的H-供体相互作用。对抗商业和大鼠肝脏DNase